Co-founder and Biology Lead, xCystence Bio

Ian Smyth

Role	Organisation	Sources
Co-founder and Biology Lead	xCystence Bio	-

Coverage

Stories naming Ian Smyth. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.

Funding announcement

Uniseed Invests in xCystence Bio to Advance New Therapy Targeting Genetic Kidney Disease

xCystence Bio secured pre-seed funding from Uniseed, Monash Ventures, Breakthrough Victoria, and BioCurate to develop targeted protein degraders for treating genetic kidney disease.

Uniseed 3 Aug 2026 BioCurate Breakthrough Victoria Monash University Monash Ventures Pre-Seed Fund Uniseed xCystence Bio Ian Smyth Ingmar Wahlqvist Dr John Kurek Paul Stupple

Something wrong? Tell us

Ian Smyth

Roles

Coverage

Uniseed Invests in xCystence Bio to Advance New Therapy Targeting Genetic Kidney Disease